Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 7/20 | 0.47 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.33 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.32 |
| ▸ | CDK9 | P50750 | 1/20 | 0.32 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.31 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.31 |
| ▸ | SYK | P43405 | 4/20 | 0.31 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.30 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21393417 | 0.86 | TRPA1 (0.47) | TRPA1SYK | |
| SCHEMBL21363489 | 0.82 | TRPA1 (0.44) | TRPA1KAT2BSYKMKNK1MKNK2 | |
| SCHEMBL21363503 | 0.77 | TRPA1 (0.42) | TRPA1ADORA2AADORA1SYK | |
| SCHEMBL21393345 | 0.75 | TRPA1 (0.39) | TRPA1KAT2BADORA2ASYKMKNK1 | |
| SCHEMBL21363702 | 0.73 | ADORA2A (0.45) | TRPA1ADORA2AADORA1 | |
| SCHEMBL22477725 | 0.72 | ADORA2A (0.37) | TRPA1ADORA2AADORA1 | |
| SCHEMBL22477724 | 0.71 | TRPA1 (0.46) | TRPA1 | |
| SCHEMBL21363535 | 0.71 | TRPA1 (0.46) | TRPA1SYKMKNK1MKNK2 | |
| SCHEMBL21363480 | 0.70 | TRPA1 (0.38) | TRPA1ADORA2AADORA1 | |
| SCHEMBL25100649 | 0.66 | ADORA2A (0.47) | TRPA1ADORA2AADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10710994-B2 | Oxadiazole transient receptor potential channel inhibitors | GENENTECH, INC. (US) | 2020-07-14 | — | — | US | disclosed |
| US-20190284179-A1 | OXADIAZOLE TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS | GENENTECH, INC. (US) | 2019-09-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190284179-A1 | OXADIAZOLE TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS | TRPA1, TRPV1, TRPV3 | TRPA1 1/4885KAT2B 2797/4885CCNT1 1873/4885 |
| US-10710994-B2 | Oxadiazole transient receptor potential channel inhibitors | TRPA1, TRPV1, TRPV3 | TRPA1 1/4885KAT2B 2797/4885CCNT1 1873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.